Dstock, we all need to realize that all the data being discussed is for a trial that didn't have the benefit of Poly-ICLC or any other therapeutic that has more recently been found to add tremendously to the benefit. I'm not saying that certain types may not do better, but we may find that worst case is 5 year survival at 50% and best case it's over 70%.
Just saying that the improvement when these other therapeutics is so great that there will be no doubt that all patients should be getting the vaccine.
I suspect that Dr. Liau and her team, as well as others, continue to work on protocol improvements that will take these results even higher. DCVax-L has the potential of making GBM considered as one of the more treatable cancers. The real question is whether it will prove to be much the same when used with many of the other deadliest cancers, like pancreatic.
I may be wrong, but I believe that once approved for GBM, other trials to add other of the deadliest cancers to the label can be completed quickly, by regulator standards, perhaps in as little as 3 to 5 years.
Of course if it were up to me they'd look at the anecdotal data and not require a trial at all, but of course it's not up to me.
Gary
Bullish
Market Data 
Markets 
AI
